All News
Deep remission in SLE – what is it, and can we achieve it?
Recent reports on small numbers of lupus patients treated with CAR-T cells directed against CD19+ B lymphocytes have generated considerable excitement, not so much because the initial response to this therapy was favorable, but because after follow-up durations of two years or longer the patients were reported to have an ongoing clinical remission without the need for further treatment and in the absence of most autoantibodies. This state has been referred to in terms such as “immunological remission” or “resetting the immune system”, suggesting that an important and potentially permanent change had occurred. Perhaps we can call it a Deep Remission, for now. So what is this Deep Remission?
Read Article
Lessons Learned from a Lupus Registry: Two sides of one coin?
I want to talk about a large Canadian registry that sometimes doesn't get as much airtime. Our group is called CaNIOS: Canadian Network for Improved Outcomes in SLE. We've enrolled more than a thousand patients, seen at least annually and some for many years. These patients are incident or prevalent and they've consented to be in the database. So what have we learned looking at kid-onset versus adult-onset lupus?
Read Article
Comparing EULAR (2025) and ACR (2020) Guidelines on Safety of Lupus Medications in Pregnancy
Attendees at the 2025 RheumaPreg meeting were excited to discuss the newly released EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation. Table 1 summarizes the major recommendations from EULAR (2025) and the American College of Rheumatology (2020) reproductive guidelines for commonly used medications in SLE. It should be noted that these two sets of guidelines largely align, however, the updated EULAR guidelines have included some additional medications incorporating data from the last five years.
Read Article
Links:
Links:
